Table 3.
Treatments and 30-day mortality rates of 43 episodes of CRE bacteremia
| Variable | N (% of total) | 30-day mortality (%) |
|---|---|---|
| All episodes of CRE bacteremia | 43 (100) | 23/43 (53) |
| Empirical therapy within 12 hours of BSI onset | ||
| Active empirical therapy1 | 6 (14) | 1/6 (17) |
| Inactive empirical therapy | 37 (86) | 22/37 (59) |
| Definitive antimicrobial regimen2,3 | ||
| Died before ever received active therapy | 9 (21) | 9/9 |
| Single Gram-negative agent | 10 (23) | 4/10 |
| Aminoglycoside monotherapy | 5 (12) | 4/5 |
| Fluoroquinolone monotherapy | 3 (7) | 0/3 |
| Two Gram-negative agents | 16 (37) | 6/16 |
| Polymyxin B and tigecycline | 5 (12) | 2/5 |
| Aminoglycoside and tigecycline | 3 (7) | 0/3 |
| Aminoglycoside and carbapenem | 3 (7) | 3/3 |
| Three Gram-negative agents | 8 (19) | 4/8 |
| Polymyxin B, aminoglycoside and carbapenem | 3 (7) | 2/3 |
| Bacteremia characteristics | ||
| Polymicrobial | 11 (26) | 9/11 (82) |
| Monomicrobial | 32 (74) | 14/32 (44) |
| Klebsiella pneumoniae | 21 (49) | 11/21 (52) |
| Other types of CRE | 11 (26) | 3/11 (27) |
1
Active therapy was defined as receipt of an antimicrobial agent to which the bloodstream isolate tested susceptible in vitro.
2
Definitive therapy was defined as antimicrobial agents administered on the day after final antimicrobial susceptibility testing results were reported.
3
30-day mortality represented as # of patients who died within 30 days / total # of patients.